Your browser doesn't support javascript.
loading
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.
Su, Bin; Yao, Cheng; Zhao, Qing-Xia; Cai, Wei-Ping; Wang, Min; Lu, Hong-Zhou; Chen, Yuan-Yuan; Liu, Li; Wang, Hui; He, Yun; Zheng, Yu-Huang; Li, Ling-Hua; Chen, Jin-Feng; Yu, Jian-Hua; Zhu, Biao; Zhao, Min; Sun, Yong-Tao; Lun, Wen-Hui; Xia, Wei; Sun, Li-Jun; Dai, Li-Li; Jiang, Tai-Yi; Wang, Mei-Xia; Zheng, Qing-Shan; Peng, Hai-Yan; Wang, Yao; Lu, Rong-Jian; Hu, Jian-Hua; Xing, Hui; Shao, Yi-Ming; Xie, Dong; Zhang, Tong; Zhang, Fu-Jie; Wu, Hao.
Afiliação
  • Su B; Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Yao C; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China.
  • Zhao QX; Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan 450061, China.
  • Cai WP; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China.
  • Wang M; Institute of HIV/AIDS, The First Hospital of Changsha, Changsha, Hunan 410005, China.
  • Lu HZ; Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
  • Chen YY; Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan 450061, China.
  • Liu L; Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
  • Wang H; Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China.
  • He Y; Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China.
  • Zheng YH; Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
  • Li LH; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China.
  • Chen JF; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China.
  • Yu JH; Department of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang 310023, China.
  • Zhu B; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310003, China.
  • Zhao M; National Clinical Research Center for Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
  • Sun YT; Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, China.
  • Lun WH; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
  • Xia W; Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Sun LJ; Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Dai LL; Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Jiang TY; Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Wang MX; Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Zheng QS; Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
  • Peng HY; Beijing Co-CRO Medical Development Co., Ltd., Beijing 100711, China.
  • Wang Y; Beijing Co-CRO Medical Development Co., Ltd., Beijing 100711, China.
  • Lu RJ; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China.
  • Hu JH; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China.
  • Xing H; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
  • Shao YM; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
  • Xie D; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China.
  • Zhang T; Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
  • Zhang FJ; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
  • Wu H; Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Chin Med J (Engl) ; 133(24): 2919-2927, 2020 Nov 25.
Article em En | MEDLINE | ID: mdl-33252379
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adult / Humans País/Região como assunto: Asia Idioma: En Revista: Chin Med J (Engl) Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adult / Humans País/Região como assunto: Asia Idioma: En Revista: Chin Med J (Engl) Ano de publicação: 2020 Tipo de documento: Article